Open AccessThe Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19
Author(s) -
А. У. Сабитов,
P. Sorokin,
S. U. Dashutina
Publication year - 2021
Publication title -
antibiotiki i himioterapiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 11
ISSN - 0235-2990
DOI - 10.37489/0235-2990-2021-66-1-2-33-37
Subject(s) - tolerability , covid-19 , medicine , coronavirus , adverse effect , virology , intensive care medicine , outbreak , infectious disease (medical specialty) , disease
Aim. Evaluation of the ecacy, safety, and tolerability of Riamilovir (trade name «Triazavirin®») in patients with mild COVID-19. Materials and methods. The randomized open-label study included 120 patients with clinical and epidemiological manifestations of coronavirus infection and its laboratory (PCR) conrmation. Results. The ecacy, safety, as well as good tolerability of Riamilovir in the treatment of new coronavirus infection (COVID-19) have been established. Conclusion. The results of the study on the ecacy, safety, and tolerability of Riamilovir allow us to recommend it as a means of etiotropic therapy of the new coronavirus infection (COVID-19).